WuXi Reports Expanded Research Deal With J&J And Higher Profits, But Also Sharper Risks Sparked By Global Financial Crisis
This article was originally published in PharmAsia News
Executive Summary
BEIJING - WuXi PharmaTech reported strong earnings growth for the third quarter, but also cautioned that the financial crisis sweeping across the globe would cut into profits for the whole of 2008
You may also be interested in...
China’s WuXi Pharma Tech Shakes Up Its Board After Tumultuous Year
The West's financial morass could ultimately prod the world's pharmaceutical giants to outsource more research and development to lower-cost China, and to WuXi PharmaTech, CEO says.
China’s WuXi Pharma Tech Shakes Up Its Board After Tumultuous Year
The West's financial morass could ultimately prod the world's pharmaceutical giants to outsource more research and development to lower-cost China, and to WuXi PharmaTech, CEO says.
China’s WuXi PharmaTech Launches Shake-up In Board Of Directors
BEIJING - Shanghai-based WuXi PharmaTech, China's leading pharmaceutical contract research organization, has reshuffled its board of directors, with one member resigning from the board and two others joining the company's management elite